EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial

Hongnan Mo, Yongpei Yu, Xiaoying Sun, Hewei Ge, Lanlan Yu, Xiuwen Guan, Jingtong Zhai, Aihua Zhu, Yuhan Wei, Jinjing Wang, Xiaoyan Yan, Haili Qian und 2 weitere

Nature Medicine · 2024-09 · 30 (9) · 2528-2539

DOI: 10.1038/s41591-024-03088-2 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Nature Medicine, online erschienen am 05.07.2024. Verfasst von Hongnan Mo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Breast Neoplasms, Administration, Metronomic, Bayes Theorem, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China (National Science Foundation of China).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It remains unclear whether metronomic chemotherapy is superior to conventional chemotherapy when combined with immune checkpoint blockade. Here we performed a phase 2 clinical trial of metronomic chemotherapy combined with PD-1 blockade to compare the efficacy of combined conventional chemotherapy and PD-1 blockade using Bayesian adaptive randomization and efficacy monitoring. Eligible patients had metastatic HER2-negative breast cancer and had not received more than one prior line of standard chemotherapy. Patients (total n = 97) were randomized to receive (1) metronomic vinorelbine (NVB) monotherapy (n = 11), (2) NVB plus anti-PD-1 toripalimab (n = 7), (3) anti-angiogenic bevacizumab, NVB and toripalimab (n = 27), (4) conventional cisplatin, NVB and toripalimab (n = 26), or (5) metronomic cyclophosphamide, capecitabine, NVB and toripalimab (the VEX cohort) (n = 26). The primary endpoint was disease control rate (DCR). Secondary objectives included progression-free survival (PFS) and safety. The study met the primary endpoint. The VEX (69.7%) and cisplatin (73.7%) cohorts had the highest DCR. The median PFS of patients in the VEX cohort was the longest, reaching 6.6 months, followed by the bevacizumab (4.0 months) and cisplatin (3.5 months) cohorts. In general, the five regimens were well tolerated, with nausea and neutropenia being the most common adverse events. An exploratory mass cytometry analysis indicated that metronomic VEX chemotherapy reprograms the systemic immune response. Together, the clinical and translational data of this study indicate that metronomic VEX chemotherapy combined with PD-1 blockade can be a treatment option in patients with breast cancer. ClinicalTrials.gov Identifier: NCT04389073 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAdministration, MetronomicBayes TheoremProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisHumansFemaleMiddle AgedAdultAgedCyclophosphamideImmune Checkpoint InhibitorsVinorelbineBevacizumab

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanCyclophosphamideImmune Checkpoint InhibitorsVinorelbineBevacizumab

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Biostatistics, Peking University Clinical Research Institute, Beijing, China.
  • Department of Medical Oncology, Cancer Hospital of HuanXing ChaoYang District, Beijing, China.
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. qian…
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xubinghe@csco.or…

Förderung

  • National Natural Science Foundation of China (National Science Foundation of China)

Zitieren

APA

Mo, H., Yu, Y., Sun, X., Ge, H., Yu, L., Guan, X., Zhai, J., Zhu, A., Wei, Y., Wang, J., Yan, X., Qian, H., Xu, B., & Ma, F. (2024). Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nature Medicine, 30(9), 2528-2539. https://doi.org/10.1038/s41591-024-03088-2

Vancouver

Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nature Medicine. 2024;30(9):2528-2539. doi:10.1038/s41591-024-03088-2

BibTeX
@article{Mo2024,
  author = {Mo, Hongnan and Yu, Yongpei and Sun, Xiaoying and Ge, Hewei and Yu, Lanlan and Guan, Xiuwen and Zhai, Jingtong and Zhu, Aihua and Wei, Yuhan and Wang, Jinjing and Yan, Xiaoyan and Qian, Haili and Xu, Binghe and Ma, Fei},
  title = {Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {9},
  pages = {2528--2539},
  doi = {10.1038/s41591-024-03088-2}
}
Kostenlos starten →